Company profile for Axovia Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families, and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting t...
Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families, and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting the most debilitating aspects of the neurological, metabolic, and retinal dysfunctions.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
London BioScience Innovation Centre 2 Royal College Street London NW1 0NH
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/05/15/3081986/0/en/Axovia-Therapeutics-Unveils-New-Preclinical-Data-for-AXV-201-for-Treatment-of-Genetic-Obesity-Caused-by-MC4R-Mutations-at-ASGCT.html

GLOBENEWSWIRE
15 May 2025

https://www.globenewswire.com/news-release/2025/05/13/3079937/0/en/Axovia-Therapeutics-Presents-New-Preclinical-Data-for-AXV-101-for-the-Treatment-of-Blindness-Associated-with-BBS-Mutations-at-ASGCT.html

GLOBENEWSWIRE
13 May 2025

https://www.globenewswire.com/news-release/2025/04/28/3069672/0/en/Axovia-Therapeutics-Announces-Three-Upcoming-Poster-Presentations-at-ASGCT.html

GLOBENEWSWIRE
28 Apr 2025

https://prnewswire.com/news-releases/viralgen-and-axovia-partner-to-manufacture-an-investigational-gene-therapy-for-retinal-dystrophy-in-bardet-biedl-syndrome-bbs-patients-302357167.html

PR NEWSWIRE
22 Jan 2025

https://www.globenewswire.com/news-release/2024/10/30/2971660/0/en/A-Race-Against-Blindness-Grants-1-Million-Supporting-Axovia-Therapeutics-Planned-Clinical-Trial-for-Bardet-Biedl-Syndrome-BBS.html

GLOBENEWSWIRE
30 Oct 2024

https://www.globenewswire.com//news-release/2024/10/24/2968482/0/en/Rhythm-Pharmaceuticals-and-Axovia-Therapeutics-Announce-Joint-Research-Collaboration-in-Bardet-Biedl-Syndrome.html

GLOBENEWSWIRE
24 Oct 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty